AbbVie Inc. (NYSE:ABBV) Shares Acquired by Catalina Capital Group LLC

Catalina Capital Group LLC raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 5.5% in the fourth quarter, HoldingsChannel reports. The firm owned 10,670 shares of the company’s stock after acquiring an additional 557 shares during the period. Catalina Capital Group LLC’s holdings in AbbVie were worth $1,896,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. S.A. Mason LLC increased its holdings in shares of AbbVie by 0.8% during the fourth quarter. S.A. Mason LLC now owns 12,745 shares of the company’s stock valued at $2,265,000 after purchasing an additional 104 shares during the period. Princeton Global Asset Management LLC lifted its holdings in AbbVie by 0.9% in the fourth quarter. Princeton Global Asset Management LLC now owns 29,932 shares of the company’s stock worth $5,319,000 after purchasing an additional 273 shares during the period. Chicago Capital LLC increased its stake in AbbVie by 0.6% during the 4th quarter. Chicago Capital LLC now owns 53,003 shares of the company’s stock valued at $9,419,000 after buying an additional 307 shares during the period. HHM Wealth Advisors LLC increased its stake in AbbVie by 51.2% during the 4th quarter. HHM Wealth Advisors LLC now owns 9,027 shares of the company’s stock valued at $1,604,000 after buying an additional 3,058 shares during the period. Finally, CFM Wealth Partners LLC raised its position in shares of AbbVie by 3.5% during the 4th quarter. CFM Wealth Partners LLC now owns 21,955 shares of the company’s stock worth $3,901,000 after buying an additional 752 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares in the company, valued at approximately $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Price Performance

ABBV opened at $183.90 on Monday. The firm has a market capitalization of $324.98 billion, a P/E ratio of 63.85, a PEG ratio of 1.77 and a beta of 0.58. The stock has a fifty day moving average of $176.57 and a 200-day moving average of $185.06. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $207.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 244.01% and a net margin of 9.22%. During the same period in the previous year, the company earned $2.79 earnings per share. Equities analysts forecast that AbbVie Inc. will post 10.09 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Leerink Partnrs raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Friday, November 22nd. BMO Capital Markets dropped their price objective on AbbVie from $228.00 to $208.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 12th. Sanford C. Bernstein began coverage on AbbVie in a report on Thursday, October 17th. They issued a “market perform” rating and a $203.00 price objective for the company. Piper Sandler Companies reaffirmed an “overweight” rating and set a $220.00 target price on shares of AbbVie in a report on Tuesday, December 17th. Finally, Wells Fargo & Company upped their price target on shares of AbbVie to $195.00 and gave the company a “buy” rating in a report on Tuesday, November 19th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $205.00.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.